LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced on July 31, 2026, that it has entered into an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module. This module aims to facilitate access to designated laboratory and scientific services, marking a significant step in the company's expansion beyond patient-facing telemedicine.
Under the agreement, LataMed AI's Venezuelan operating subsidiary, LATAMEDAI VE, will collaborate with IVIC on the design, development, testing, and implementation of a digital interface. This interface is intended to allow authorized business and institutional users to request available laboratory services, schedule appointments, monitor request status, access approved reports, and complete payment-related processes. The proposed module is designed to provide a centralized digital workflow for organizations seeking scientific and laboratory services in sectors such as healthcare, pharmaceuticals, food production, agriculture, and related industries.
The specific services available through the platform will be determined by IVIC, with implementation adhering to technical, operational, security, and legal requirements established by both parties. LataMed AI will work with IVIC to define functional requirements, user-access procedures, data architecture, payment workflows, document-management capabilities, and a phased testing and implementation process. The platform's functionality may include electronic service requests, appointment scheduling, request-status tracking, secure payment facilitation, and controlled access to laboratory reports.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI, commented, "This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery. Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform."
The initiative aligns with LataMed AI's broader strategy of developing digital infrastructure that connects patients, healthcare professionals, pharmacies, insurers, payment providers, wellness organizations, institutions, and other participants in the healthcare and scientific-services ecosystem. Management believes the proposed module could expand the company's capabilities by demonstrating how its technology can support institutional and enterprise workflows beyond telemedicine.
If successfully implemented, the module may provide a framework adaptable for other institutional and enterprise service environments in Venezuela and Latin America. However, any future expansion would depend on separate agreements, technical readiness, regulatory requirements, and institutional needs. The agreement establishes a development and evaluation framework but does not guarantee specific implementation dates, user adoption, service volume, revenue, or profitability.
This partnership is particularly relevant as it underscores the growing intersection of technology and scientific services in emerging markets. For business leaders, the development highlights the potential for digital platforms to streamline complex institutional processes, reduce bureaucratic inefficiencies, and improve access to critical laboratory services. In Venezuela, where such services may be challenging to access, this module could enhance operational efficiency for organizations relying on scientific testing. Furthermore, it positions LataMed AI as a player in the broader digital transformation of healthcare and scientific sectors in Latin America, potentially setting a precedent for similar initiatives across the region.
LataMed AI is also developing AI-supported platforms like CardioAI, PulmoAI, and NeuroAI, which are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. These platforms remain under development and subject to regulatory approvals.
For more information about LataMed AI and its initiatives, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
